FRONTIER1 (NCT04204408) was a phase 1/2 study that investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of Mim8 in healthy participants and multiple ascending doses (MAD) of Mim8 in people with hemophilia A, with or without FVIII inhibitors. The gene discussed is F8; the disease is hemophilia A.